Literature DB >> 18279475

Reversible posterior leukoencephalopathy syndrome associated with bevacizumab/doxorubicin regimen.

Franck Bürki, Kattalin Badie, Philippe Bartoli, Pascale Bernard, Jean Louis Montastruc, Haleh Bagheri.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18279475      PMCID： PMC2432493          DOI： 10.1111/j.1365-2125.2008.03119.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  9 in total

1.  Reversible posterior leukoencephalopathy syndrome following CHOP chemotherapy for diffuse large B-cell lymphoma.

Authors:  M J Edwards; R Walker; S Vinnicombe; C Barlow; P MacCallum; J M Foran
Journal:  Ann Oncol       Date:  2001-09       Impact factor: 32.976

2.  Hypertension as a predictive factor of Sunitinib activity.

Authors:  O Rixe; B Billemont; H Izzedine
Journal:  Ann Oncol       Date:  2007-06       Impact factor: 32.976

3.  Reversible posterior leukoencephalopathy syndrome and bevacizumab.

Authors:  Peter Glusker; Larry Recht; Barton Lane
Journal:  N Engl J Med       Date:  2006-03-02       Impact factor: 91.245

4.  Reversible posterior leukoencephalopathy syndrome and bevacizumab.

Authors:  Cevher Ozcan; Stuart J Wong; Parameswaran Hari
Journal:  N Engl J Med       Date:  2006-03-02       Impact factor: 91.245

5.  Reversible posterior leukoencephalopathy syndrome induced by sunitinib.

Authors:  German Martín; Lorena Bellido; Juan Jesus Cruz
Journal:  J Clin Oncol       Date:  2007-08-10       Impact factor: 44.544

6.  Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer.

Authors:  Jeffrey A Allen; Ashish Adlakha; Peter R Bergethon
Journal:  Arch Neurol       Date:  2006-10

Review 7.  The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review.

Authors:  Ferry A L M Eskens; Jaap Verweij
Journal:  Eur J Cancer       Date:  2006-11-13       Impact factor: 9.162

8.  Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer.

Authors:  Christopher G Willett; Yves Boucher; Emmanuelle di Tomaso; Dan G Duda; Lance L Munn; Ricky T Tong; Daniel C Chung; Dushyant V Sahani; Sanjeeva P Kalva; Sergey V Kozin; Mari Mino; Kenneth S Cohen; David T Scadden; Alan C Hartford; Alan J Fischman; Jeffrey W Clark; David P Ryan; Andrew X Zhu; Lawrence S Blaszkowsky; Helen X Chen; Paul C Shellito; Gregory Y Lauwers; Rakesh K Jain
Journal:  Nat Med       Date:  2004-01-25       Impact factor: 53.440

9.  Reversible posterior leukoencephalopathy syndrome after treatment of diffuse large B-cell lymphoma.

Authors:  Mark D Haefner; R Daniele Siciliano; Lucas A Widmer; Barbara M Vogel Wigger; Sonia Frick
Journal:  Onkologie       Date:  2007-02-02
  9 in total
  5 in total

1.  Looking back: editors' pick of 2008.

Authors:  Y K Loke; A Somogyi; L D Lewis; M Schachter; A F Cohen; J M Ritter
Journal:  Br J Clin Pharmacol       Date:  2009-01       Impact factor: 4.335

2.  Atypical reversible posterior leukoencephalopathy syndrome (RPLS) induced by cediranib in a patient with metastatic rectal cancer.

Authors:  Christina A K Kim; Julie Price-Hiller; Quincy S Chu; Keith Tankel; Ron Hennig; Michael B Sawyer; Jennifer L Spratlin
Journal:  Invest New Drugs       Date:  2014-05-23       Impact factor: 3.850

3.  Improving adverse drug reaction reporting in hospitals: results of the French Pharmacovigilance in Midi-Pyrénées region (PharmacoMIP) network 2-year pilot study.

Authors:  Mireille Gony; Kattalin Badie; Agnès Sommet; Julien Jacquot; Dominique Baudrin; Pierre Gauthier; Jean Louis Montastruc; Haleh Bagheri
Journal:  Drug Saf       Date:  2010-05-01       Impact factor: 5.606

Review 4.  Posterior reversible encephalopathy syndrome induced by anti-VEGF agents.

Authors:  Camille Tlemsani; Olivier Mir; Pascaline Boudou-Rouquette; Olivier Huillard; Karin Maley; Stanislas Ropert; Romain Coriat; François Goldwasser
Journal:  Target Oncol       Date:  2011-11-17       Impact factor: 4.493

5.  Atypical reversible leucoencephalopathy syndrome after bevacizumab/folfox regimen for metastatic colon cancer.

Authors:  Narimane Salmi; Ibrahim Elghissassi; Khadija Bellahammou; Asmaa Lakhdissi; Hind Mrabti; Hassan Errihani
Journal:  Case Rep Oncol Med       Date:  2014-10-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.